In this episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, and Jodi Smith, PhD, the Global Medical Strategy Lead in Thoracic Oncology at Pfizer, discuss the value of Medical Affairs. While they agree that there’s a cost associated with bringing Medical Affairs into the early development of a drug, they see a clear and measurable benefit, from accelerated enrollment to having a solid foundation for commercialization. Through their many years in different roles within Medical Affairs, they know that to achieve these benefits, organizations need to have the right team members in the right roles with the agility to work in an ever-changing landscape as well as provide strategic thinking, a diversity of audience, and continuity throughout the product lifecycle - from clinical development through commercialization and beyond.

Curiosity, empathy, authenticity, strength. Good leaders express many key characteristics and come in all shapes and sizes. In this special International Women’s Day episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, Aree Cheshire, PhD, VP of Client Strategy in UK Communications at Lumanity, and Amber Gilbert, MBA, Global Practice Lead for Value, Access & Outcomes at Lumanity, meet to discuss excellence in leadership. During their conversation they touch on whether good leadership qualities are innate or learned, how to balance being a leader versus a “do-er”, and how to approach leadership differently during challenging times. Other areas of focus include how strategic thinking plays into leadership, and what types of skills or knowledge are required to succeed as a leader. Finally, they discuss how women in leadership roles today can help pave the way for the next generation of strong female leaders.

Now, more than ever, the patient voice is being heard by the pharmaceutical industry. In this episode, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, and Len Lichtenfeld, MD, MACP meet to discuss the ways patients are providing advisement in drug development and valuation. After hearing about Len’s extensive experience, they delve into the new regulatory changes coming to pharma and biotech that will require the patient experience to be taken into consideration during the drug development process. They conclude by discussing how the patient experience is having an impact on the valuation of new drugs.